Equities Analysts Set Expectations for ABOS FY2029 Earnings

On March 28, 2025, analysts at HC Wainwright announced their earnings per share (EPS) expectations for Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS). According to HC Wainwright analyst A. Fein, Acumen is anticipated to report earnings of ($2.03) per share for the fiscal year 2029. The firm has assigned a 'Buy' rating to the stock, along with a price target of $11.00. This is a contrast to the current consensus estimate for Acumen Pharmaceuticals, which stands at ($1.56) per share for the full year.

In a separate report, UBS Group has cut their target price for Acumen Pharmaceuticals from $6.00 to $4.00 while still maintaining a 'Buy' rating for the stock.

Market Performance of Acumen Pharmaceuticals

As of Monday, ABOS traded down 7.6%, opening at $1.10. The stock's fifty-day simple moving average sits at $1.37, and the two-hundred-day simple moving average is $1.97. Acumen has a quick ratio of 10.43, indicating strong liquidity, and a current ratio of 10.43 as well, along with a low debt-to-equity ratio of 0.14. The company's market capitalization is estimated at $66.09 million, with a price-to-earnings ratio of -0.80 and a beta of 0.02. Over the past year, the stock reached a low of $1.06 and a high of $4.06.

Recently, Acumen Pharmaceuticals released their earnings results on March 27th, revealing a loss of ($0.62) per share for the quarter, which was below analysts' consensus expectation of ($0.47) by ($0.15).

Hedge Fund Activities with Acumen Pharmaceuticals

Institutional investors and hedge funds have made notable adjustments to their holdings in Acumen Pharmaceuticals in recent months. For instance, Geode Capital Management LLC increased its stake by 6.5% during the third quarter, now owning 864,528 shares valued at $2,144,000 after acquiring an additional 52,395 shares. State Street Corp raised its holdings by 18.3%, bringing its total to 516,406 shares worth $1,281,000 following the purchase of 79,841 additional shares. SG Americas Securities LLC also increased its stake in Acumen by 44.2%, securing 25,631 shares valued at $44,000 after acquiring 7,859 shares.

Moreover, Barclays PLC raised its holdings in Acumen by a substantial 189.1%, now possessing 61,997 shares valued at $154,000 after a recent purchase of 40,551 shares. Lastly, JPMorgan Chase & Co. augmented their ownership by 252.8%, ending up with 63,066 shares valued at $156,000 following an acquisition of 45,189 shares. Overall, hedge funds and institutional investors currently control 71.01% of the stock.

Insider Transactions Within Acumen Pharmaceuticals

In other developments, CFO Matt Zuga sold 28,902 shares of the company on January 23rd at an average price of $1.72, resulting in a total transaction value of $49,711. Following this sale, Zuga retains 231,744 shares, valued at approximately $398,599. This sale reflects an 11.09% decrease in his ownership stake. In a similar fashion, CEO Daniel Joseph O’Connell sold 47,778 shares on January 3rd at an average price of $1.84, bringing the total transaction to $87,911.52. O'Connell now holds 454,707 shares, worth about $836,660.88, marking a 9.51% decrease in ownership. Over the last quarter, insiders have sold a total of 131,526 shares worth $233,124, and corporate insiders own 7.10% of the total shares issued by the company.

Company Overview

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focusing on the development of targeted therapies aimed at treating Alzheimer’s disease. The firm is dedicated to advancing its lead immunotherapy drug candidate, sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed its Phase I clinical trials targeting soluble amyloid-beta oligomers.

Further Information

• Five stocks that outperform Acumen Pharmaceuticals
• Defining penny stocks: A complete guide
• Three buyable stocks poised for recovery
• Insights into Congressional stock trading
• Meta’s rapidly expanding $20 billion AI ad initiative
• A simple guide to shorting stocks in five steps
• Latest news on robotaxi developments and their implications for shares

For those interested in receiving daily news and analysis regarding Acumen Pharmaceuticals and related companies, sign up for a free daily newsletter.

Earnings, Stocks, Analysis